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Atypical motifs in the cytoplasmic region of the inhibitory
immune co-receptor LAG-3 inhibit T cell activation
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T cell activation is tightly regulated by both stimulatory and
inhibitory co-receptors and has been a focus in the development
of interventions for managing cancer or autoimmune diseases.
Targeting the inhibitory co-receptors programmed cell death
1 (PD-1) and cytotoxic T lymphocyte–associated protein 4
(CTLA-4) has successfully eradicated tumors but induced
immune-related adverse events in humans andmice. The bene-
ficial and adverse effects of targeting these co-receptors high-
light their importance in cancer immunity and also autoimmu-
nity. Although the therapeutic potencies of other inhibitory
co-receptors are under extensive investigation, their inhibitory
mechanisms and their functional differences are notwell under-
stood. Here we analyzed the inhibitory mechanisms of lympho-
cyte activation gene-3 (LAG-3), another inhibitory co-receptor,
by using an in vitro T cell activation system and a high-affinity
anti-LAG-3 antibody that strongly interfereswith the binding of
LAG-3 to its ligand.We found that the expression level of LAG-3
strongly correlates with the inhibitory function of LAG-3, sug-
gesting that LAG-3 functions as a rheostat rather than as a
breaker of T cell activation. By evaluating the inhibitory capac-
ities of various LAG-3 variants relative to their expression levels,
we found that LAG-3 transduces two independent inhibitory
signals through an FXXL motif in the membrane-proximal
region and the C-terminal EX repeat. These motifs have not
been reported previously for inhibitory co-receptors, suggesting
that LAG-3 inhibits T cell activation through a nonredundant
inhibitory mechanisms along with the other inhibitory co-re-
ceptors. Our findings provide a rationale for combinatorial
targeting of LAG-3 and the other inhibitory co-receptors to
improve cancer immunotherapy.
T cell activation is tightly regulated by stimulatory and inhibi-
tory co-receptors that modulate the T cell receptor (TCR)3 signal
(1–3). Because of the recent success of tumor immunotherapy
targeting inhibitory co-receptors, cytotoxic T lymphocyte–
associated protein 4 (CTLA-4) and programmed cell death 1
(PD-1), the therapeutic potencies of other inhibitory co-recep-
tors are investigated extensively (4). However, their inhibitory
mechanisms as well as their functional differences or the
molecular coordination among inhibitory and stimulatory co-
receptors are still poorly understood.
Lymphocyte activation gene-3 (LAG-3), an inhibitory co-re-
ceptor with structural similarities to CD4, has been shown to
negatively regulate autoimmunity, cancer immunity, and infec-
tious immunity by itself or in collaboration with other inhibi-
tory co-receptors, including PD-1 (5–10). LAG-3 deficiency
exacerbates type I diabetes in non-obese diabetic mice (5, 8).
Mice deficient in both LAG-3 and PD-1 develop lethal autoim-
mune myocarditis, and simultaneous blockade of PD-1 and
LAG-3 efficiently eradicates tumors and clears pathogens in
mice (7, 8, 10). Therefore, LAG-3 is a potent therapeutic target
of immunotherapies for cancer as well as other diseases (11).
LAG-3 has four Ig-like domains, called domain 1 (D1) to D4,
in its extracellular (EC) region. LAG-3 has been reported
to associate with major histocompatibility complex class II
(MHCII), using itsD1with higher affinity thanCD4, and inhibit
T cell activation by interfering with the engagement of CD4 by
MHCII (12, 13). However, LAG-3 can inhibit T cell activation
independently of CD4, and the molecular mechanism of inhi-
bition by LAG-3 has been enigmatic (8). We have recently
found that LAG-3 does not bind to MHCII universally but
binds selectively to a stable complex of peptides and MHCII
(pMHCII) and preferentially inhibits the activation of T cells
reactive to stable pMHCII (14). We have also demonstrated
that LAG-3 does not interfere with CD4–pMHCII and TCR–
pMHCII interactions. Instead, the inhibitory function of
LAG-3 requires its intracellular (IC) region, suggesting that
LAG-3 transduces the inhibitory signal via its IC region (14).
The IC region of LAG-3, consisting of about 60 amino acid
residues, lacks a typical signaling motif with a known signaling
mechanism such as the immunoreceptor tyrosine–based in-
hibitory motif and immunoreceptor tyrosine–based switch
motif. However, amino acid sequences from different species
show substantial similarity. Workman et al. (15) reported that
the KIEELE sequence in the middle of the IC region is con-
served among species and is required for LAG-3 to inhibit
antigen-dependent activation of 3A9 hybridoma T cells. They
also demonstrated that the amino acid substitution of Lys in the
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KIEELE sequence to Ala was enough to abrogate the inhibitory
capacity of LAG-3 (15).However, theother regionshavenotbeen
extensively analyzed, and how this Lys transduces the inhibitory
signal is currentlyunknown. Iouzalen et al. (16) identifiedLAG-3–
associated protein (LAP) as a molecule that binds to the C-termi-
nal region of LAG-3 with 10 to 15 repeats of Glu and favoring but
not limited to Pro (EX repeat). Currently, the function of LAP as
well as the EX repeat is unknown. Thus, themolecular basis of the
inhibitory signal by LAG-3 remains elusive.
In this study, we used an in vitro T cell activation system and
high-affinity anti-LAG-3 antibody (Ab) that strongly interfered
with the interaction of LAG-3 and pMHCII to analyze the
inhibitory function of LAG-3. We demonstrated that the
expression level of LAG-3 strongly correlated with the inhibi-
tory function of LAG-3. Intriguingly, deletion of the KIEELE
sequence did not abrogate the inhibitory function of LAG-3.
Instead, we found that LAG-3 transduces two independent
inhibitory signals through an FXXL motif in the membrane-
proximal region (PR) and the C-terminal EX repeat. To date,
these motifs have not been reported for the other inhibitory
co-receptors, suggesting that LAG-3 inhibits T cell activation
using nonredundant inhibitory mechanisms with the other
inhibitory co-receptors.
Results
Evaluation of anti-mouse LAG-3monoclonal Abs
Monoclonal Abs are useful and essential for analyzing the
physical and functional properties of molecules. Although the
C9B7W clone of the anti-mouse LAG-3 Ab is widely used as a
blocking Ab ofmouse LAG-3, C9B7Whas been reported not to
interferewith the binding of LAG-3 toMHCII but postulated to
induce conformational changes of LAG-3 to attenuate its func-
tion (13). We have recently developed the TKB58 clone of the
anti-moue LAG-3 Ab that can strongly block binding of LAG-3
to pMHCII (14). We first characterized TKB58 and C9B7W as
well as theTKB27 clone of the anti-mouse LAG-3Ab, whichwe
developed by immunizing LAG-3–deficient mice with the
recombinant protein of the mouse LAG-3 EC region. We gen-
erated chimeric molecules of mouse and human LAG-3 in
which one of the four Ig-like domains of mouse LAG-3 is
swapped with the corresponding Ig-like domain of human
LAG-3 and tested their reactivity to TKB58, TKB27, and
C9B7W. In accordance with the former report, C9B7W recog-
nized D2 of mouse LAG-3 because it failed to recognize the
chimeric molecule with human D2 (Fig. 1A). TBK58 and
TBK27 recognized D1 and D4 of mouse LAG-3, respectively
(Fig. 1A). Next we tested the capacity of TKB58, TKB27, and
C9B7W to block the binding of soluble LAG-3 protein (LAG-
3–EC) to stable pMHCII on IIA1.6 B lymphoma cells (14). As
shown in Fig. 1B, TKB58 but not TKB27 blocked LAG-3–EC
binding to IIA1.6 cells. On the other hand, C9B7W slightly
reduced the staining intensity of LAG-3–EC in IIA1.6 cells,
suggesting that the conformational change induced by C9B7W
might result in weak attenuation of the interaction between
LAG-3 and pMHCII.
To examine the capacities of TKB58, TKB27, and C9B7W to
block the inhibitory function of LAG-3, we used DO11.10
hybridoma T cells, which recognize the 323–339 segment of
chicken ovalbumin (pOVA323–339) in the context of I-Ad. Aswe
have reported before, LAG-3 efficiently inhibited the activation
and the secretion of IL-2 fromDO11.10 T cells upon co-culture
with pOVA323–339–pulsed IIA1.6 cells (Fig. 1C) (8). TKB58
completely blocked the inhibitory effects of LAG-3 at as low as
0.5 g/ml, whereas TKB27 did not block the inhibitory effects
of LAG-3 even at 25 g/ml (Fig. 1,D and E). In agreement with
the former report, we could observe the blocking effect by
C9B7W, albeit to a lesser extent than TKB58 (13). However,
C9B7W did not completely block the inhibitory effect of LAG-3,
even at 25 g/ml, probably because C9B7W attenuates LAG-3
functionby inducing the conformational changeofLAG-3butnot
bymasking the binding surface of LAG-3 to pMHCII (Fig. 1E).
Then we measured binding affinities of TKB58, TKB27, and
C9B7W to LAG-3 using biolayer interferometry (Fig. 2). The
association rate of TKB58 was 26 and 23 times faster than that
of C9B7W and TKB27, whereas the dissociation rate of TKB58
was 2.1 and 3.6 times slower than that of TKB27 and C9B7W.
Accordingly, the KD value of TKB58 was 48 and 94 times
smaller than that of TKB27 andC9B7W, indicating that TKB58
binds to mouse LAG-3 much more strongly than TKB27 and
C9B7W (Fig. 2).
Correlation of the cell surface amount of LAG-3 and its
inhibitory effect
LAG-3 is not expressed on naive T cells but inducibly
expressed on T cells upon activation (17). Although the stron-
ger TCR signal induces higher LAG-3 expression, the correla-
tion of the cell surface amount of LAG-3 and its inhibitory
effect has not been elucidated. Therefore, we overexpressed
LAG-3 on DO11.10 T cells to various levels using seven differ-
ent promoters (pLTR, pEF1, pCAG, p-actin, pCMV, pSV40,
and pMC1) with or without a polyadenylation (poly(A)) signal,
which generally prolongs the longevity of transcripts (Fig. 3, A
and B). The amount of cell surface LAG-3 was calculated rela-
tive to that of DO11.10 T cells expressing LAG-3 under pLTR.
LAG-3–dependent inhibitory effects were calculated by com-
paring the amount of IL-2 in the presence or absence of an
anti-LAG-3–blockingAb (TKB58). As shown in Fig. 3,C andD,
the inhibitory effect of LAG-3 showed a strong positive corre-
lation with the cell surface amount of LAG-3 (R2  0.9287).
Intriguingly, the inhibitory effect of LAG-3 was not saturated,
even when LAG-3 was expressed with the strongest promoter
tested (pLTR). These results indicate that LAG-3 functions as a
rheostat rather than as a breaker of T cell activation.
Requirement of the PR for the inhibitory function of LAG-3
Although the KIEELE sequence in the middle of the IC
region of LAG-3 has been reported to be essential for LAG-3
function (15), we could not reproduce the result in our experi-
mental system using DO11.10 T cells (Fig. 4, A–C). Therefore,
we examined the requirements of the PR (amino acids 467–
492) and the EX repeat (amino acids 493–521) of LAG-3 for its
inhibitory function. We generated deletion mutants of LAG-3
and introduced them into DO11.10 T cells (Fig. 4, A and B).
Because deletion mutations affected the cell surface expression
level of LAG-3 to variable degrees, and we observed a strong
Inhibitorymechanisms of LAG-3–dependent T cell suppression
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correlation between the cell surface amount of LAG-3 and its
inhibitory effect (Fig. 3D), we evaluated the inhibitory capacity
of each LAG-3 mutant by comparing its expression level and
inhibitory effect with the reference values obtained from the
panel of DO11.10 T cells expressing LAG-3 to variable degrees
(Fig. 3D). In accordance with the former observation, LAG-
3IC failed to inhibit IL-2 secretion fromDO11.10 T cells upon
antigen stimulation, suggesting that LAG-3 inhibits T cell acti-
vation by transducing an inhibitory signal via its IC region (Fig.
4, D and E) (14, 15). Intriguingly, LAG-3PR, but not LAG-
3EX or LAG-3KIEELE, showed a substantially reduced
inhibitory capacity, indicating that the PR, but not the KIEELE
sequence, is required for the inhibitory function of LAG-3 (Fig.
4, D and E).
Requirement of the FXXLmotif in the PR for the inhibitory
function of LAG-3
To further characterize the PR, a series of mutants with ala-
nine substitutions in five consecutive amino acid residues in the
PR were generated and tested for their expression levels on
DO11.10 T cells and inhibitory function (Fig. 5A). LAG-3
mutants with 473–477A and 476–480A substitutions showed
Figure 1. Characterization of anti-mouse LAG-3 Abs. A, recognition ofmouse LAG-3 D1, D4, and D2 by TKB58, TKB27, and C9B7W clones of anti-mouse
LAG-3 Abs. DO11.10 T cells expressing chimeric LAG-3 with the indicated human-derived Ig-like domain were stained with the indicated Abs. Mean
fluorescence intensity (MFI) is indicated. B, capacity of anti-mouse LAG-3 Abs to block binding of LAG-3–EC to stable pMHCII on IIA1.6 cells. IIA1.6 cells
were stained with LAG-3–EC (5 g/ml) in the presence or absence of TKB58, TKB27, or C9B7W (5 g/ml), and bound LAG-3–EC was detected with the
secondary Ab (anti-DYKDDDDK tag Ab). MFI is indicated. ctrl, control. C, capacity of anti-mouse LAG-3 Abs to block LAG-3 function. DO11.10 T cells with
or without LAG-3 were stimulated with pOVA-pulsed (1 M) IIA1.6 cells in the presence or absence of TKB58, TKB27, and C9B7W (1 g/ml). The
concentration of IL-2 in the culture supernatant was determined by ELISA. Numbers denote the percentage of LAG-3–dependent inhibition of IL-2
production in the presence of the indicated Ab.D, titration of the capacity of TKB58 to block LAG-3 function. DO11.10 T cells with or without LAG-3 were
stimulated as in C in the presence of the indicated amount of TKB58 or its isotype control. The concentration of IL-2 in the culture supernatant was
determined by ELISA. E, comparison of the capacity of anti-mouse LAG-3 Abs to block LAG-3 function. The percentage of LAG-3–dependent inhibition
of IL-2 production in the presence of the indicated amount of each Ab is shown. Data are themean S.D. of technical duplicates in one experiment. Data
are representative of more than three independent experiments.
Inhibitorymechanisms of LAG-3–dependent T cell suppression
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reduced inhibitory capacity to a similar level as LAG-3PR,
indicating that the responsible amino acid residues are located
between Arg-473 to His-480 (Fig. 5, B–D). Then we tested sin-
gle alanine substitutionmutants and found that LAG-3–F475A
and LAG-3–L478A showed reduced inhibitory capacity to a
similar level as LAG-3PR, suggesting that Phe-475 and Leu-
Figure 2. Binding affinities of TKB58, TKB27, and C9B7W to mouse LAG-3. A–C, binding affinities of anti-mouse LAG-3 Abs to mouse LAG-3 protein.
LAG-3–ECwas immobilized on the biosensor chip, and the association of TKB58 (A), TKB27 (B), andC9B7W (C) at the indicated concentrationwasmonitored by
biolayer interferometry. Chips were washed with PBS to analyze the dissociation kinetics; ka, kd, and kD are shown. Data are representative of more than two
independent experiments.
Figure 3. Correlation between the amount of LAG-3 and its inhibitory effect. A, schematic of retroviral expression vectors. Mouse LAG-3 cDNA was
overexpressed inDO11.10 T cells using the indicated promoterswith orwithout a poly(A) signal. B, DO11.10 T cells with various expression levels of LAG-3. The
expression levels of LAG-3 were evaluated by flow cytometry using an anti-LAG-3 Ab (TKB58). MFI is indicated. C, LAG-3–dependent inhibition of IL-2
production in DO11.10 T cells with various LAG-3 expression levels. DO11.10 T cells overexpressing LAG-3 under the indicated promoter with or without a
poly(A) signal were stimulated with pOVA-pulsed (1 M) IIA1.6 cells in the presence of anti-LAG-3–blocking Ab (TKB58) or its isotype control (ctrl Ig). The
concentration of IL-2 in the culture supernatant was determined by ELISA.D, the correlation between the percentage of LAG-3–dependent inhibition and the
expression level of LAG-3. The amount of LAG-3 was calculated relative to that of DO11.10 T cells expressing LAG-3 under the LTR promoter. The solid line
represents the regression line, and dashed lines represent 95% prediction intervals. The correlation coefficient is shown. Data are themean S.D. of technical
duplicates in one experiment. Data are representative of more than three independent experiments.
Inhibitorymechanisms of LAG-3–dependent T cell suppression
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478 play pivotal roles in the PR-dependent inhibitory function
of LAG-3 (Fig. 5, E–H). LAG-3 with both F475A and L478A
mutations also showed reduced inhibitory capacities to a simi-
lar level as LAG-3PR, LAG-3–473–477A, and LAG-3–476–
480A (Fig. 5, F–H). Therefore, Phe-475 and Leu-478 likely
function in the same inhibitory process, and we named this
motif the FXXL motif.
Weak EX repeat–dependent inhibition of T cell activation by
LAG-3
Although the inhibitory capacity of LAG-3PR and F475A/
L478A was substantially attenuated, they still weakly inhibited
IL-2 production fromDO11.10T cells upon activation. Because
LAG-3IC completely lacked the inhibitory function, this
residual inhibitory effect is likely mediated by the EX repeat. As
expected, by deleting the EX repeat of LAG-3–F475A/L478A,
the residual inhibitory effect was completely abrogated (Fig. 6,
A and B). Therefore, LAG-3 likely inhibits T cell activation by
using two distinctmechanisms that are dependent on the FXXL
motif and the EX repeat.
The LAG-3 mutant that was defective in both FXXL
motif– and EX repeat–dependent inhibitory mechanisms
(LAG-3EX/F475A/L478A) rather increased IL-2 production,
indicating that LAG-3EX/F475A/L478A functioned as a co-
stimulator (Fig. 6,A andB). The co-stimulatory effect depended
on the interaction of LAG-3EX/F475A/L478A with pMHCII
because the anti-LAG-3–blocking Ab (TKB58) completely
canceled the additive effect. As mentioned above, LAG-3 has a
structural similarity to CD4 in the EC but not IC region. CD4 is
known to associate with Lck, which is essential for initiation of
the TCR signal. In agreement with previous reports (18, 19),
overexpression of CD4 not only augmented the production of
IL-2 upon activation but also rendered DO11.10 T cells depen-
dent on CD4 for activation, as the anti-CD4–blocking Ab
(GK1.5) completely abrogated IL-2 production rather than
merely canceling the additive effect. These results suggest that
the PR of LAG-3 may associate with a signaling molecule that
additively augments the strength of the TCR signal (Fig. 6C).
Discussion
In this study, by using an in vitroT cell activation system and
high-affinity anti-LAG-3Ab that interferes with the interaction
of LAG-3 and stable pMHCII, we analyzed the inhibitory func-
tion of LAG-3 against T cell activation. First we demonstrated
that the cell surface amount of LAG-3 strongly correlated with
its inhibitory function, which indicates that LAG-3 functions as
a rheostat rather than as a breaker of T cell activation. LAG-3 is
not expressed on naive T cells but inducibly expressed on T
cells upon activation (17). The protein kinase C signaling path-
way has been reported to regulate the expression level of LAG-3
by controlling its trafficking from the lysosomal compart-
ment to the cell surface (20). The cell surface expression
level of LAG-3 is also regulated by shedding of the EC region
by two transmembrane metalloproteases, ADAM10 and
ADAM17 (21). These findings clearly indicate that the inhib-
itory effect of LAG-3 was not saturated even when LAG-3
was expressed with the strongest promoter tested. In addi-
tion, changes in the amount of LAG-3 on the cell surface
Figure 4. Requirement of the PR region for the inhibitory function of LAG-3. A, amino acid sequences of the IC region of LAG-3 and its deletion mutants.
The PR, KIEELE sequence, and EX repeat are indicated by red, black, and blue lines, respectively. Numbers denote the position of the amino acid from the
translation initiation site.B, expression levels of LAG-3mutants inDO11.10T cells. DO11.10T cells expressingLAG-3and its indicatedmutantswere stainedwith
TKB58 and analyzed by flow cytometry. C–E, defective inhibition of IL-2 production fromDO11.10 T cells by LAG-3 lacking its PR and IC region. DO11.10 T cells
expressingLAG-3and itsmutantswere stimulatedwithpOVA-pulsed (1M) IIA1.6 cells in thepresenceof anti-LAG-3–blockingAb (TKB58) or its isotype control
(ctrl Ig).C, the concentrationof IL-2 in the culture supernatantwasdeterminedbyELISA. The relative expression level and the inhibitory effect of LAG-3mutants
are plotted in the standard plot shown in Fig. 3D. D, LAG-3mutants with weaker function are highlighted in red. E, the inhibitory effect relative to intact LAG-3
with the same expression level is shown for the indicated LAG-3 mutants. Data are the mean S.D. of technical duplicates in one representative experiment
from three independent experiments (C) or themean S.D. of three independent experiments (D and E). p values comparing the expression-adjusted relative
inhibition of the indicated LAG-3 mutants with that of intact LAG-3 are shown (Student’s t test, E).
Inhibitorymechanisms of LAG-3–dependent T cell suppression
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directly affected the inhibitory effect of LAG-3, indicating
that regulation of its cell surface amount is effective for the
regulation of T cell activation.
The expression level of LAG-3 has been reported to differ
largely depending on the cell type. CD4 T cells with exhaus-
tion-like phenotypes have been reported to express a high
Inhibitorymechanisms of LAG-3–dependent T cell suppression
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amount of LAG-3, whereas a small subset of intestinal CD4 T
cells with regulatory function have been reported to weakly
express LAG-3 (7, 22–25). The impact of LAG-3 on cell-auton-
omous function may thus differ among different types of cells.
In addition, a stronger TCR signal induces higher LAG-3
expression, suggesting that the induction of LAG-3 likely serves
as negative feedback to prevent excess activation (8).
By dissecting the IC region of LAG-3, we found that LAG-3
inhibits T cell activation by using two distinct mechanisms that
are dependent on the FXXLmotif in the PR and the EX repeat at
the C terminus. Because LAG-3EX showed an inhibitory
capacity comparable with intact LAG-3, FXXL motif–depen-
dent inhibition predominates over EX repeat–dependent inhi-
bition, at least regarding inhibition of IL-2 production by
DO11.10 T cells upon activation. On the other hand, EX
repeat–dependent inhibition functions complementarily in the
absence of FXXLmotif–dependent inhibition. Intriguingly, the
LAG-3 mutant that is defective in both FXXL motif– and EX
repeat–dependent inhibitory mechanisms provided co-stimu-
lation, suggesting that the PR of LAG-3 may contain a co-stim-
ulatory motif(s) in addition to co-inhibitory motifs. Further
analyses are required to reveal the physiological meaning of the
co-stimulatory potential of LAG-3.
Because the FXXL motif resembles the YXXL sequence in
the immunoreceptor tyrosine–based inhibitory motif, phos-
photyrosine-independent signaling adaptor proteins may be
involved in the inhibitory signal via the FXXL motif in LAG-3.
For example, -adaptin, which is involved in endocytosis of
membranemolecules, has been reported to recognize the FXXL
motif in -arrestin2 (26). The C-terminal tail of platelet-de-
rived growth factor  receptor is also rich in Glu and Pro.
Intriguingly, this C-terminal tail has been reported to inhibit its
tyrosine kinase activity autonomously (27). Although LAG-3
itself does not have tyrosine kinase activity, the EX repeat of
LAG-3 may also inhibit another tyrosine kinase that is acti-
vated by antigen stimulation. Currently, how the FXXLmotif
and EX repeat regulate TCR-proximal and downstreammol-
ecules is unknown. Further analyses are expected to delin-
eate the precise molecular mechanisms of how these motifs
independently or cooperatively regulate signaling pathways
in T cell activation.
LAG-3 inhibits the proliferation of T cells and production of
cytokines, such as IL-2 and IFN, from T cells (8, 28, 29). In
addition, LAG-3 has been reported to play critical roles in
regulatory T cells (24). In this study, we clearly demonstrate
that LAG-3 inhibits IL-2 production from T cells upon anti-
Figure 5. Requirement of the FXXLmotif in the PR for the inhibitory function of LAG-3.A–D, defective inhibition of IL-2 production by LAG-3with alanine
substitutions at 473–477 and 476–480. A, amino acid sequences of the IC regions of LAG-3 and its mutants are shown. Substituted alanine residues and
mutants with weaker function are colored in red. B, DO11.10 T cells expressing LAG-3 and its mutants were stimulated with pOVA-pulsed (1M) IIA1.6 cells in
the presence of anti-LAG-3–blocking Ab (TKB58) or its isotype control (ctrl Ig). The concentration of IL-2 in the culture supernatant was determined by ELISA.
C, the relative expression level and the inhibitory effect of LAG-3 mutants are plotted on the standard plot shown in Fig. 3D. LAG-3 mutants with weaker
function are highlighted in red. D, the inhibitory effect relative to intact LAG-3 with the same expression level is shown for the indicated LAG-3 mutants. E–H,
defective inhibition of IL-2 production by LAG-3 with alanine substitutions at 475 and 480. Amino acid sequences (E) and inhibitory function (F–H) of the
indicated LAG-3 mutants are shown as in A–D. Data are the mean S.D. of technical duplicates in one representative experiment from three independent
experiments (B and F) or themean S.D. of three independent experiments (C,D,G, andH). p values comparing the expression-adjusted relative inhibition of
indicated LAG-3 mutants with that of intact LAG-3 are shown (Student’s t test, D and H).
Figure6. EX repeat–dependent inhibitionof T cell activationbyLAG-3.A andB, EX repeat–dependent partial inhibitory effect of the LAG-3mutant lacking
the FXXL motif. A, amino acid sequences of the IC region of LAG-3 and its mutants. B, DO11.10 cells with LAG-3 and its mutants were stimulated with
pOVA-pulsed (1 M) IIA1.6 cells in the presence of anti-LAG-3–blocking Ab (TKB58) or its isotype control (ctrl Ig). The concentration of IL-2 in the culture
supernatant was determined by ELISA. C, different manners of co-stimulation by CD4 and the LAG-3 mutant lacking both the FXXL motif and EX repeat.
DO11.10 T cells overexpressing mouse CD4 were stimulated with IIA1.6 cells pulsed with the indicated amount of pOVA in the presence or absence of
anti-CD4–blockingAb (GK1.5). The concentration of IL-2 in the culture supernatantwas determinedby ELISA. Data are themean S.D. of technical duplicates
in one experiment. Data are representative of more than three independent experiments. ND, not detected.
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gen stimulation by using the FXXL motif and EX repeat. The
requirement of both or either of these motifs in LAG-3–de-
pendent regulation of other T cell functions remains to be
verified.
We have reported recently that LAG-3 does not bind to
MHCII universally but selectively binds to stable pMHCII and
preferentially inhibits the activation of T cells reactive to stable
pMHCII (14). Identification of the FXXLmotif and EX repeat in
this study further supports the idea that LAG-3 accumulates at
the immunological synapse and transduces an inhibitory signal
via its IC region to attenuate the TCR-proximal signal.
As mentioned above, we could not reproduce the former
observation by Vignali et al. (15) that deletion of the KIEELE
sequence abrogated the inhibitory function of LAG-3. Although
the reason for this discrepancy is currently unknown, it should be
noted that the PR was not analyzed in the study, and thus the
relative effects of the PR and the KIEELE sequence have not been
compared (15).Basedonourobservation, deletionof thePRmight
have shown greater effect compared with the deletion of KIEELE
sequence under the former experimental condition as well. In
addition, the expression levels of LAG-3mutants substantially dif-
fered amongdifferentmutants. Becauseweobserved a strongpos-
itive correlation between the cell surface amount and the inhibi-
tory effect of LAG-3, we need to take into consideration the
expression level of mutants. Otherwise, wemay under- or overes-
timate the inhibitory capacity of mutants. By comparing the
expression level and the inhibitory effect of mutants with the ref-
erence values obtained from the panel ofDO11.10T cells express-
ing LAG-3 to variable degrees, we could obtain unambiguous
results.
While we were preparing this manuscript, Chen and co-
workers (30) reported that LAG-3 inhibits T cell activation
by associating with fibrinogen-like protein 1 (FGL1). Al-
though the exact contribution of FGL1 and stable pMHCII to
the inhibitory function of LAG-3 needs future verification,
complete blockade of LAG-3 function by TKB58, which
interferes with the binding between D1 of LAG-3 and
pMHCII, strongly suggests that stable pMHCII is primarily
involved in inhibition by LAG-3 (14).
Because of the success of tumor immunotherapy targeting
CTLA-4 and PD-1, the therapeutic potencies of other inhibi-
tory co-receptors are being extensively explored. However,
their actual inhibitory mechanisms, functional differences, and
collaboration are not well understood. Here we demonstrated
that LAG-3 transduced two independent inhibitory signals
through the FXXL motif in the PR and the C-terminal EX
repeat. These motifs have not been reported previously for
inhibitory co-receptors, suggesting that LAG-3 inhibits T cell
activation using nonredundant inhibitorymechanismswith the
other inhibitory co-receptors. Thus, combinatorial therapy of
LAG-3 with the other inhibitory co-receptors is expected to
provide synergistic effects.
Experimental procedures
Cell culture
DO11.10 T and IIA1.6 cells, which were kindly provided by
Tasuku Honjo (Kyoto University) and Tomohiro Kurosaki
(Osaka University), respectively, were cultured in RPMI 1640
medium (Gibco) supplemented with 10% (v/v) FBS (Biowest),
0.5 mM monothioglycerol (Wako), 2 mM L-alanyl-L-glutamine
dipeptide (Gibco), 100 units/ml penicillin (Nacalai Tesque),
and 100 g/ml streptomycin (Nacalai Tesque). Plat-E cells,
which were kindly provided by Toshio Kitamura (University of
Tokyo), were maintained in DMEM (Gibco) supplemented
with 10% (v/v) FBS, 100 units/ml penicillin (Nacalai Tesque),
and 100 g/ml streptomycin (Nacalai Tesque).
Plasmids and retroviral gene transduction
Fragments of cDNA were amplified by PCR and cloned into
retroviral expression plasmid vectors modified from pFB-ires-
Neo (Agilent), with which cDNAs are transcribed under pLTR.
Mutant cDNAs with deletions and amino acid substitutions
and chimeric cDNAs of mouse and human LAG-3 were gener-
ated by overlap extension PCR. To control the expression lev-
els, fragments of cDNA were cloned into retroviral expression
plasmid vectors modified from pSUPER.retro.puro (Oligo-
Engine), the promoter region of which was replaced with
promoters of human elongation factor 1 (EF-1), cytome-
galovirus enhancer/chicken -actin (CAG), -actin, pCMV
(cytomegalovirus), SV40 (simian virus 40), and MC1 (polyoma
virus enhancer/herpes simplex virus thymidine kinase) coupled
with or without a poly(A) signal. Plasmids were transfected
using FuGENEHD (Promega) into Plat-E cells cultured in high-
glucose DMEM (Gibco) supplemented with 20% (v/v) FBS, 100
units/ml penicillin, and 100 g/ml streptomycin, and superna-
tants containing viruses were used to transduce genes into tar-
get cells. Infected cells were selected with G418 (Wako) or
puromycin (Sigma-Aldrich) or by cell sorting.
Soluble protein
The fragment of cDNA encoding D1 to D4 of mouse LAG-3
(LAG-3–EC) was amplified by PCR. The five-stranded coiled-
coil domain of cartilage oligomeric matrix protein (COMP)
(31) with a DYKDDDDK tag, tobacco etch virus protease cleav-
age site, and a PA tag (GVAMPGAEDDVV) was added to the C
terminus of LAG-3–EC for the pentamer. The Fc region of
human IgG1 (hIgG1Fc) was added to the C terminus of LAG-
3–EC for the dimer. A strep-tag II (WSHPQFEK) was added to
the C terminus of LAG-3–EC for the monomer. Chimeric
cDNAs were cloned into expression vectors modified from
pEBMulti-Neo (Wako). Plasmids were transfected into Plat-E
cells using Avalanche-Omni transfection reagent (EZ Biosys-
tems), and the culture supernatants were collected after 48 h.
Pentameric LAG-3–EC was purified using anti-PA tag Ab
beads (Wako), followed by cleavage by TurboTEV Protease
(Accelagen). Dimeric LAG-3–EC was purified using protein G
(GE Healthcare).
Mice
BALB/cCrSlc-Lag3/ (LAG-3aida/aida) mice (8) were
housed under specific pathogen-free conditions in environ-
mentally controlled clean rooms. All mouse protocols were
approved by the Animal Experimentation Committee of
Tokushima University. All experimental procedures complied
with institutional regulations in accordance with the Act on
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Welfare andManagement of Animals and related guidelines in
Japan.
Generation of anti-mouse LAG-3monoclonal Abs
BALB/cCrSlc-Lag3/ mice were immunized with dimeric
mouse LAG-3–EC, and lymph node cells of immunized mice
were fused with SP2/o cells using the envelope of hemaggluti-
nating virus of Japan (GenomONE-CF, Ishihara Sangyo Kai-
sha). Culture supernatants of hybridoma clones were tested for
their reactivity to DO11.10 T cells overexpressing mouse
LAG-3 by flow cytometry.
Antibody and flow cytometry analysis
Cells were stained with the indicated Abs. Data were
obtained with Gallios (Beckman Coulter) and analyzed using
FlowJo (Tree Star). Anti-mouse LAG-3 Ab (C9B7W) and its
isotype control (rat IgG1, eBRG1) were purchased from
Thermo Fisher Scientific. The anti-DYKDDDDK tag (L5) Ab
and isotype control for TKB58 (mouse IgG1, MOPC-21) were
purchased fromBioLegend. The FITC-labeled F(ab’)2 fragment
of the goat anti-mouse IgG (HL)Abwas purchased from Jack-
son ImmunoResearch Laboratories. The FITC-labeled goat
anti-rat IgG (HL) Ab was purchased from Southern Biotech.
TKB58 and TKB27 were purified from culture supernatants of
hybridomas using protein G–Sepharose. Purified TKB58 was
labeled with CF633-Dye (Biotium).
Biolayer interferometry
Monomeric mouse LAG-3–EC with a streptavidin tag was
immobilized on streptavidin-coated biosensor chips (Pall
ForteBio), and the association of anti-mouse LAG-3 Abs at dif-
ferent concentration was monitored using BLItz (Pall Forte-
Bio). Chips were washed with PBS to analyze the dissociation
kinetics. The association rate constant (ka), dissociation rate
constant (kd), and dissociation constant (kD) were calculated
using BLItz Pro software.
Stimulation of DO11.10 T cells
DO11.10 T cells infected with or without retroviral vectors
containing the indicated cDNAs (5  104 cells/well) were co-
cultured with IIA1.6 cells (1  104 cells/well) with cognate
OVA323–339 peptide (ISQAVHAAHAEINEAGR,95% purity,
Sigma-Aldrich Japan or eurofins Genomics) for 24 h. The con-
centration of IL-2 in the culture supernatant was quantified by
ELISA (BioLegend). To block mouse LAG-3–mediated inhibi-
tion, anti-mouse LAG3 Ab or isotype matched control IgG was
added throughout the co-culture assay. The percentage of
LAG-3–dependent inhibition of IL-2 production was calcu-
lated as the ratio of IL-2 concentration in the presence or
absence of anti-LAG-3–blockingAb (unless specified, TKB58).
To block CD4, anti-mouse CD4 Ab (5 g/ml, GK1.5, Thermo
Fisher Scientific) was added throughout the co-culture assay.
The estimated inhibitory effect by intact LAG-3 at the same
expression level of each LAG-3 mutant was deduced from the
regression line obtained from the panel of DO11.10 T cells
expressing LAG-3 to variable degrees. The expression-adjusted
inhibitory function of each LAG-3 mutant was calculated by
dividing the raw percentage of inhibition by each LAG-3
mutant by the estimated percentage of inhibition by intact
LAG-3 at the same expression level.
Statistical analysis
Two-tailed unpaired Student’s t test was used to evaluate
statistical significance.
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